0001181431-14-005003.txt : 20140204 0001181431-14-005003.hdr.sgml : 20140204 20140204165427 ACCESSION NUMBER: 0001181431-14-005003 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20130702 FILED AS OF DATE: 20140204 DATE AS OF CHANGE: 20140204 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARATANA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001509190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 383826477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1901 OLATHE BOULEVARD CITY: KANSAS CITY STATE: KS ZIP: 66103 BUSINESS PHONE: 913.951.2130 MAIL ADDRESS: STREET 1: 1901 OLATHE BOULEVARD CITY: KANSAS CITY STATE: KS ZIP: 66103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lichter Jay CENTRAL INDEX KEY: 0001376355 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35952 FILM NUMBER: 14572970 MAIL ADDRESS: STREET 1: C/O ARATANA THERAPEUTICS, INC. STREET 2: 1901 OLATHE BOULEVARD CITY: KANSAS CITY STATE: KS ZIP: 66103 4/A 1 rrd401055.xml LICHTER F4/A X0306 4/A 2013-07-02 2013-07-03 0 0001509190 ARATANA THERAPEUTICS, INC. PETX 0001376355 Lichter Jay C/O ARATANA THERAPEUTICS, INC. 1901 OLATHE BOULEVARD KANSAS CITY KS 66103 1 0 1 0 COMMON STOCK 2013-07-02 4 P 0 500000 6.0 A 4170543 I BY LIMITED PARTNERSHIP COMMON STOCK 9025 I BY LIMITED LIABILITY COMPANY This amended Form 4 is filed solely for the purpose of reporting the shares purchased as reported on Table 1 Line 1. The aggregate shares reported reflect a 2-share decrease from the Reporting Person's Form 4 filed on July 3, 2013 as a result of the rounding of Series A, B and C Convertible Preferred Stock which converted into shares of the Issuer's Common Stock on a 1-for-0.601685 basis upon the closing of the Issuer's initial public offering. Held by Avalon Ventures IX, L.P. ("Avalon Ventures LP"). The Reporting Person is a managing director of Avalon Ventures LP and shares voting and dispositive power over the shares held by Avalon Ventures LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. Held by Avalon Ventures IX Management, LLC ("Avalon Ventures LLC"). The Reporting Person is a manager of Avalon Ventures LLC and shares voting and dispositive power over the shares held by Avalon Ventures LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. Exhibit List: Exhibit 24 - Power of Attorney. /s/ John C. Ayres, Attorney-in-Fact for Jay Lichter 2014-02-04 EX-24. 2 rrd360925_408931.htm POWER OF ATTORNEY rrd360925_408931.html
					POWER OF ATTORNEY
					JAY LICHTER

	With respect to holdings of and transactions in securities issued by Aratana Therapeutics, Inc.,
the undersigned hereby constitutes and appoints the individuals named on Schedule A attached hereto and as
may be amended from time to time, or any of them signing singly, with full power of substitution and
resubstitution, to act as the undersigned's true and lawful attorney-in-fact to:


1.	prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the United States
	Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any
	other documents necessary or appropriate to obtain and/or regenerate codes and passwords enabling the
	undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the
	Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;


2.	execute for and on behalf of the undersigned, Forms 3, 4, and 5 in accordance with Section 16 of
	the Securities Exchange Act of 1934, as amended, and the rules thereunder;


3.	do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to
	complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto,
	and timely file such form with the SEC and any stock exchange or similar authority; and


4.	take any other action of any type whatsoever in connection with the foregoing which, in the opinion of
	such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned,
	it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant
	to this Power of Attorney shall be in such form and shall contain such terms and conditions as such
	attorney-in-fact may approve in such attorney-in-facts discretion.


	The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and
every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and
powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally
present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that
such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done
by virtue of this Power of Attorney and the rights and powers herein granted.


	The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the
request of the undersigned, are not assuming, nor is any Company assuming, any of the undersigned's
responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.


	This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to
file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by
Aratana Therapeutics, Inc., unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.


	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 4th day of
 June, 2013.


/s/ Jay Lichter
----------------
Jay Lichter





					Schedule A


	Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and Resubstitution


	1.  Steven St. Peter, M.D., President and Chief Executive Officer
	2.  Craig Tooman, Chief Financial Officer
        3.  John C. Ayres, General Counsel